Payment overview · 2025
General Payments
$2,420.26
152 reported records · 13 companies
Healthcare provider profile · identity verified
Charlene Vitale, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ROCHESTER, NY · NPI 1720099856
Verified facts
What the public records show
CMS Open Payments records show Charlene Vitale, M.D. received $2,420.26 in general payments during 2025 across 152 reported records.
Amgen Inc. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $603.49 | 24.9% | 35 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $525.22 | 21.7% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $291.23 | 12.0% | 27 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $287.25 | 11.9% | 19 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $250.19 | 10.3% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $223.97 | 9.2% | 27 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $71.51 | 3.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.36 | 2.1% | 7 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.83 | 1.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.97 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.41 | 1.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.97 | 0.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.86 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,420.26 | 152 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $603.49 | 35 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $603.49 | 35 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $388.82 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $369.04 | 6 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $327.91 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $287.25 | 19 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $270.88 | 17 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $250.19 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $193.67 | 20 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $178.98 | 18 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $112.17 | 13 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $105.38 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $97.56 | 7 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $71.51 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $50.36 | 7 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $32.71 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $6.42 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $6.42 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $6.42 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $5.40 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 212 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 235 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 272 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 57 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
220 | 52 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
235 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
272 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
212 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
45 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 834 | 234 |
| Levothyroxine Sodium | Levothyroxine Sodium | 665 | 172 |
| Dexamethasone | Dexamethasone | 658 | 312 |
| Omeprazole | Omeprazole | 422 | 117 |
| Gabapentin | Gabapentin | 288 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 78 |
| Ozempic | Semaglutide | 272 | 51 |
| Repatha Sureclick | Evolocumab | 265 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 249 | 63 |
| Metformin Hcl | Metformin Hcl | 248 | 82 |
| Jardiance | Empagliflozin | 235 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 62 |
| Synthroid | Levothyroxine Sodium | 220 | 52 |
| Eliquis | Apixaban | 212 | 46 |
| Meloxicam | Meloxicam | 191 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 189 | 33 |
| Famotidine | Famotidine | 187 | 51 |
| Torsemide | Torsemide | 173 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 45 |
| Mounjaro | Tirzepatide | 156 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 153 | 44 |
| Bupropion Xl | Bupropion Hcl | 149 | 31 |
| Allopurinol | Allopurinol | 148 | 33 |
| Alprazolam | Alprazolam | 141 | 40 |
| Losartan Potassium | Losartan Potassium | 141 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 38 |
| Azithromycin | Azithromycin | 133 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 131 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 129 | 33 |
| Methylprednisolone | Methylprednisolone | 123 | 81 |
| Bupropion Hcl Sr | Bupropion Hcl | 111 | 34 |
| Tramadol Hcl | Tramadol Hcl | 109 | 29 |
| Clonazepam | Clonazepam | 107 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 36 |
| Fluconazole | Fluconazole | 103 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 28 |
| Carvedilol | Carvedilol | 99 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 30 |
| Metformin Hcl Er | Metformin Hcl | 94 | 28 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 93 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 85 | 60 |
| Diazepam | Diazepam | 84 | 30 |
| Lisinopril | Lisinopril | 84 | 22 |
| Montelukast Sodium | Montelukast Sodium | 84 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 84 | 25 |
| Lagevrio (Eua) | Molnupiravir | 81 | 76 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 14 |
| Celecoxib | Celecoxib | 80 | 20 |
| Lansoprazole | Lansoprazole | 77 | 20 |
| Valsartan | Valsartan | 74 | 17 |
| Alendronate Sodium | Alendronate Sodium | 73 | 16 |
| Calcitriol | Calcitriol | 73 | 18 |
| Trazodone Hcl | Trazodone Hcl | 72 | 30 |
| Valacyclovir | Valacyclovir Hcl | 70 | 32 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 69 | 20 |
| Ezetimibe | Ezetimibe | 67 | 22 |
| Pregabalin | Pregabalin | 61 | 13 |
| Atenolol | Atenolol | 60 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | 19 |
| Lorazepam | Lorazepam | 58 | 15 |
| Prednisone | Prednisone | 58 | 22 |
| Rybelsus | Semaglutide | 57 | 13 |
| Telmisartan | Telmisartan | 56 | 17 |
| Sertraline Hcl | Sertraline Hcl | 53 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 36 |
| Potassium Chloride | Potassium Chloride | 52 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Irbesartan | Irbesartan | 50 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Spironolactone | Spironolactone | 49 | 18 |
| Topiramate | Topiramate | 47 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 45 | 40 |
| Dutasteride | Dutasteride | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Methotrexate | Methotrexate Sodium | 43 | 14 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 40 | suppressed |
| Nitroglycerin | Nitroglycerin | 40 | 17 |
| Vascepa | Icosapent Ethyl | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 34 |
| Cephalexin | Cephalexin | 39 | 35 |
| Icosapent Ethyl | Icosapent Ethyl | 39 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | 24 |
| Ondansetron Odt | Ondansetron | 39 | 25 |
| Pitavastatin Calcium | Pitavastatin Calcium | 39 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 39 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 36 | suppressed |
| Furosemide | Furosemide | 35 | suppressed |
| Kerendia | Finerenone | 35 | 18 |
| Sucralfate | Sucralfate | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Estradiol | Estradiol | 26 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Livalo | Pitavastatin Calcium | 26 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Praluent Pen | Alirocumab | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Trospium Chloride | Trospium Chloride | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Edarbi | Azilsartan Medoxomil | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 12 |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Zolmitriptan | Zolmitriptan | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 13 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 13 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Risperidone | Risperidone | 12 | suppressed |
| Steglujan | Ertugliflozin/Sitagliptin Phos | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,420.26 · 152 records | Amgen Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, ELIQUIS, EOHILIA, FARXIGA, JARDIANCE, JATENZO, Kerendia, LOKELMA, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, WAINUA, XHANCE, Yorvipath, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error